CAMBRIDGE, Mass., Jun 23, 2010 (BUSINESS WIRE) --ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Timothy P. Clackson, Ph.D. has been named the company's first President of Research ...

Timothy P. Clackson - Chief Scientific Officer and President of Research & Development Frank G. Haluska - Chief Medical Officer and Senior Vice President of Clinical Research & Development Thank ...

Dr. Clackson brings to Kesmalea more than three decades of experience building oncology companies, including leading the R&D behind three approved drugs. He most recently served as Chief Executive ...

Timothy Clackson, Ph.D., has been elected as an independent member of its Board of Directors. “We are thrilled to welcome Dr. Clackson to our Board of Directors,” said Martin Driscoll ...

This independent approach is backed by Berger’s colleague Timothy Clackson, who has been with the company since 1994 and is now president of R&D. “There are many examples of companies that have ...

Timothy Clackson and Grace Clackson acquired the property at 11 Sandy Lane, Truro, from Rom P Watson and Susan B Watson on April 12, 2023. The $2,200,000 purchase price represents a price per ...

Macro Matterscategory Trump trade team chases 90 deals in 90 days. Experts say good luck with that 9:25 AM UTC Macro Matterscategory China retaliates again in Trump's trade war, prompting flight ...

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics (FORMA) today announced the appointment of Tim Clackson, Ph.D., former President, Research and Development, ARIAD Pharmaceuticals, Inc. to the ...

Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business on Wednesday, September 5, 2012 at 4:25 p.m. (ET).

Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company's business on Wednesday, June 5, 2013 at 10:00 a.m. (ET). The ...

Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will present on Tuesday, June 11 at 8:10 a.m. (CT). The Goldman Sachs 34th Annual Global Healthcare ...

Dr. Clackson brings to Kesmalea more than three decades of experience building oncology companies, including leading the R&D behind three approved drugs. He most recently served as Chief Executive ...